Foundation Healthcare’s IPO on the Singapore Exchange raised SGD242 million, valuing the company at roughly SGD1 billion, according to the filing.
Deal structure and investor response
The offering attracted strong demand, with subscriptions and indications of interest reaching about 3.8 times the shares on offer. Ten cornerstone investors committed to the deal, helping to secure the capital needed for the next growth phase.
International counsel Latham & Watkins represented the issuer and its selling shareholders. The New York‑based firm’s team was led by partner Sharon Lau, with counsel Kelly Teoh and associate Zheyi Feng handling the listing work. Tax advice came from partner Aaron Bernstein and associate Grace Jang, while regulatory support was provided by partner Laura Ferrell, counsel Meghan Carey and associate Micaela Lucero Little.
Allen & Gledhill served as the local legal adviser to the company and its vendors, which included SeaTown Private Capital Master Fund and several individual investors. The Singapore firm’s partners Tan Tze Gay, Rhys Goh and Wu Zhaoqi coordinated the equity‑capital‑markets work.
Clifford Chance advised the joint bookrunners—Jefferies, OCBC, UBS, DBS and UOB—on Singapore, U.S. federal securities and New York law. Partner Jean Thio led that team, assisted by counsel Claire Neo and associates Jun Kai Choo and Adam Fong.
Corporate advisory and regulatory coordination
A separate Clifford Chance group, headed by Singapore office managing partner Valerie Kong, provided corporate advisory services to both SeaTown Private Capital Master Fund and Foundation Healthcare. Counsel Ivan Chan, senior associate Victor Leung and associates Jia De Yam and Yuqian Zhang supported the advisory effort.
Related: KKR and SK launch Korea’s largest renewable energy platform
The IPO is expected to fund expansion across the specialist medical services, the network of medical centres and the healthcare‑technology ventures. As of the end of March 2026, the firm was the largest multi‑specialty platform in Singapore by the number of specialists and clinics.
From a broader perspective, the transaction mirrors earlier Singapore listings where strong cornerstone commitments helped smaller issuers achieve sizable market‑cap thresholds. The reliance on both local and international counsel reflects a pattern of cross‑border collaboration that has become common in the region’s capital‑markets activity.
Regulatory filings show compliance with the Singapore Exchange’s listing requirements, including disclosure of financial performance and risk factors. The prospectus noted that the proceeds would be allocated to capital expenditures, technology upgrades and potential acquisitions.
Observers noted that participation of global banks such as UBS and Jefferies demonstrated continued confidence in Singapore’s healthcare sector, even as regional economies manage post‑pandemic recovery.
Leadership indicated that the raised funds would enable the firm to broaden its specialist offerings, improve patient access and invest in digital health platforms that support telemedicine and data analytics.
Future growth looks promising.
